

Cecilie Hveding Blimark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8759286/publications.pdf>

Version: 2024-02-01

36
papers

1,807
citations

471509

17
h-index

434195

31
g-index

36
all docs

36
docs citations

36
times ranked

2563
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	3.5	356
2	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	1.4	204
3	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , 2009, 114, 791-795.	1.4	133
4	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. <i>Blood</i> , 2013, 121, 4647-4654.	1.4	128
5	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , 2012, 97, 854-858.	3.5	110
6	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. <i>European Journal of Haematology</i> , 2018, 101, 237-244.	2.2	107
7	Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , 2018, 103, 506-513.	3.5	103
8	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , 2009, 94, 1714-1720.	3.5	95
9	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	3.5	87
10	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , 2011, 118, 6284-6291.	1.4	74
11	Secondary immunodeficiency in lymphoproliferative malignancies. <i>Hematological Oncology</i> , 2016, 34, 121-132.	1.7	68
12	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. <i>International Journal of Cancer</i> , 2009, 125, 2147-2150.	5.1	63
13	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. <i>European Journal of Haematology</i> , 2017, 99, 216-222.	2.2	48
14	Percutaneous vertebroplasty at C2: case report of a patient with multiple myeloma and a literature review. <i>European Spine Journal</i> , 2007, 16, 242-249.	2.2	45
15	Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. <i>British Journal of Haematology</i> , 2014, 164, 684-693.	2.5	38
16	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <i>Haematologica</i> , 2016, 101, e145-e148.	3.5	26
17	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
18	Comorbidities in multiple myeloma and implications on survival: A population-based study. <i>European Journal of Haematology</i> , 2021, 106, 774-782.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 183-193.	2.3	16
20	Melphalan 100â€fmg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. <i>European Journal of Haematology</i> , 2011, 87, 117-122.	2.2	15
21	Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. <i>European Journal of Haematology</i> , 2022, 108, 34-44.	2.2	10
22	Outcome data from >10,000 multiple myeloma patients in the Danish and Swedish national registries. <i>European Journal of Haematology</i> , 2022, 108, 99-108.	2.2	9
23	Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. <i>European Journal of Haematology</i> , 2020, 104, 376-382.	2.2	8
24	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2021, 106, 380-388.	2.2	6
25	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. <i>Blood</i> , 2019, 134, 601-601.	1.4	5
26	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. <i>Blood</i> , 2013, 122, 1972-1972.	1.4	4
27	Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 945-945.	1.4	2
28	Lenalidomide versus lenalidomide+dexamethasone prolonged treatment after second-line lenalidomide+dexamethasone induction in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 2256-2268.	2.8	1
29	Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.. <i>Blood</i> , 2012, 120, 2970-2970.	1.4	1
30	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. <i>Blood</i> , 2015, 126, 3047-3047.	1.4	1
31	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. <i>Cancer Reports</i> , 2022, 5, e1614.	1.4	1
32	Over 10 years relative median survival in MM patients â‰‰ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e209.	0.4	0
33	Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.. <i>Blood</i> , 2007, 110, 660-660.	1.4	0
34	Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. <i>Blood</i> , 2010, 116, 4053-4053.	1.4	0
35	Abstract 5030: The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients. , 2017, , .		0
36	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1631-1631.	1.4	0